Company / Operating Cash Flow
ENDRA Life Sciences Inc. Operating Cash Flow History
FY2017-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$10.7M
FY2020
5-year range
-$10.7M / -$3.3M
FY2017-FY2020
Trend
-39.5%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$3M to -$11M over the past 2 years.
Based on SEC 10-K filings.
-$11M in FY2020.
Declined from -$3M to -$11M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, operating cash flow decreased 39.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -7.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$10.7M | -39.5% |
| FY2019 | -$7.7M | -133.3% |
| FY2018 | -$3.3M | +0.0% |
| FY2017 | -$3.3M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026